Invivyd, Inc. (NASDAQ:IVVD) Given Consensus Rating of “Hold” by Analysts

Invivyd, Inc. (NASDAQ:IVVD) has been given a consensus rating of “Hold” by the six ratings firms that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $8.00.

Several equities analysts have commented on IVVD shares. HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Invivyd in a research report on Monday, June 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Invivyd in a report on Friday, July 24th. Wall Street Zen downgraded Invivyd from a “hold” rating to a “strong sell” rating in a research report on Saturday, May 16th. Finally, BTIG Research reiterated a “buy” rating on shares of Invivyd in a report on Tuesday, July 7th.

Invivyd Price Performance

NASDAQ IVVD opened at $0.74 on Monday. The company has a fifty day moving average price of $0.82 and a 200-day moving average price of $1.30. The firm has a market cap of $218.01 million, a price-to-earnings ratio of -2.39 and a beta of 0.71. Invivyd has a 1 year low of $0.48 and a 1 year high of $3.07.

Invivyd (NASDAQ:IVVD) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.05). Invivyd had a negative net margin of 138.90% and a negative return on equity of 53.48%. The firm had revenue of $13.74 million for the quarter, compared to the consensus estimate of $18.04 million. On average, research analysts anticipate that Invivyd will post -0.5 EPS for the current fiscal year.

Hedge Funds Weigh In On Invivyd

Institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. purchased a new stake in Invivyd during the second quarter worth about $14,076,000. Deutsche Bank AG bought a new position in shares of Invivyd during the 2nd quarter valued at approximately $688,000. Bank of New York Mellon Corp bought a new position in shares of Invivyd during the 2nd quarter valued at approximately $452,000. GSA Capital Partners LLP bought a new position in shares of Invivyd during the 2nd quarter valued at approximately $578,000. Finally, Bank of America Corp DE increased its stake in shares of Invivyd by 152.9% during the 1st quarter. Bank of America Corp DE now owns 962,386 shares of the company’s stock worth $1,251,000 after purchasing an additional 581,782 shares during the last quarter. Institutional investors own 70.36% of the company’s stock.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.